Publications by authors named "M Mazzucconi"
Article Synopsis
- A study compared the effectiveness of standard-dose prednisone (PDN) and high-dose dexamethasone (HD-DXM) as first-line treatments for newly diagnosed primary immune thrombocytopenia (pITP) in adults aged 18-80.
- The trial involved 113 patients, with 52% receiving PDN and 48% receiving HD-DXM, showing initial response rates of 78.57% for PDN versus 93.88% for HD-DXM; however, the long-term responses favored PDN.
- Both treatments were well tolerated, with overall survival at 100% after 48 months, highlighting that while HD-DXM may yield quicker initial results, PDN offers more sustained
Background: Acquired Haemophilia A (AHA) patients show a high response rate to immunosuppressive therapy (IST) but few information about predictors of response and outcome are reported.
Aims: We describe a large single-centre AHA cohort, investigating prognostic variables for the 'best response' (BR), time to BR (TTBR) and overall survival (OS).
Methods: A total of 61 patients were included, collecting data from clinical charts.
Background: Non-severe hemophilia A patients have a life-long inhibitor risk. Yet, no studies have analyzed risk factors for inhibitor development after 50 factor VIII (FVIII) exposure days (EDs).
Objectives: This case-control study investigated treatment-related risk factors for inhibitor development in non-severe hemophilia A and assessed whether these risk factors were different for early versus late inhibitor development.
The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patients with primary immune thrombocytopenia (ITP) are unknown. We investigated TRA response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROTs) in 384 patients with ITP aged ≥60 years. After 3 months, 82.
View Article and Find Full Text PDF